FDA Approves Unknown Drug — TORRENT

TORRENT Pharmaceuticals announced that the FDA has approved its Abbreviated New Drug Application (ANDA) 200160 for [insert specific drug substance/product if available] on April 3, 2014, with an anticipated 180-day launch following possible patent challenges. This regulatory milestone positions TORRENT to capture market share in the [insert therapeutic area] segment, presenting a significant near-term opportunity for revenue growth despite ongoing competitive industry dynamics.